Skip to content

ICU Venous Thromboembolism Incidence Study in a Chinese Population

Using Inflammatory Markers to Predict the Development and Outcome of Venous Thromboembolism in an Intensive Care Unit

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01504087
Enrollment
200
Registered
2012-01-05
Start date
2011-05-31
Completion date
Unknown
Last updated
2012-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Venous Thromboembolism

Keywords

patient in critical care

Brief summary

Venous thromboembolism (VTE) is one of the major public health problems in Western country. More than 100,000 Americans die each year from VTE. VTE is also a common complication of critical illness,1-2 and probably related to poor outcome in this patient group. Although there are guidelines about VTE prophylaxis in acutely ill medical patients and patients in medical ICU3, they are overlooked in our daily practice frequently in our country. There are many reasons for our common practice, including inadequate knowledge for the ICU physicians, more patients with bleeding tendency in ICU and low prevalence of VTE in our (eastern) country. However, the true prevalence of VTE in ICU and if thromboprophylaxis still needed in certain high risk patients are not unknown. Besides, if there is a difference in the VTE rate between western and eastern patients, what is the underlying mechanism? The major objective of this application is to answer the first part of the problem, i.e. to delineate the scope of this problem. The specific aims of this application are as follows: * prevalence of venous thromboembolism in ICU in Taiwan * specific risk in subgroups of ICU patients * prevalence and risk factors for silent pulmonary embolism

Interventions

None listed

Sponsors

National Taiwan University Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* All patients admitted to medical ICU with age over 18 y/o are eligible

Exclusion criteria

* Patients who do not sign the informed consent will be excluded from this study

Design outcomes

Primary

MeasureTime frame
deep venous thrombosis by ultrasoundday 14 after ICU admission

Secondary

MeasureTime frame
any clinical thromboembolic eventday 14

Countries

Taiwan

Contacts

Primary ContactChi-sheng Hung, MD
dtmed186@yahoo.com.tw886-972-655354

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026